14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Aug 31, 2026
CRNX vs AKRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Aug 31, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CRNX carries a Unified Composite Score of 46.8/100 (HOLD) at $84.95 (N/M Forward P/E, -527.4% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. CRNX 46.8/100 HOLD), CRNX captures the overall institutional head-to-head verdict (3–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-527.4% vs. 0.0% operating margin) and revenue trajectory (+2336.3% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRNX vs AKRO. Trailing 12-month operating profitability (CRNX -527.4% vs AKRO 0.0%) and valuation multiples (CRNX N/M vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CRNX vs AKRO Key Questions & Quantitative Answers
As of Aug 31, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CRNX carries a Unified Composite Score of 46.8/100 (HOLD) at $84.95 (N/M Forward P/E, -527.4% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. CRNX 46.8/100 HOLD), CRNX captures the overall institutional head-to-head verdict (3–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-527.4% vs. 0.0% operating margin) and revenue trajectory (+2336.3% vs. +0.0% YoY).
CRNX leads the Growth & Scale pillar: CRNX posts +2336.3% YoY revenue growth and +0.0% YoY earnings growth on $42M TTM revenue (N/A gross margin, -527.4% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CRNX generates $42M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, CRNX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.
CRNX and AKRO trade at balanced relative valuation multiples. CRNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRNX (-42.4% ROE) versus AKRO (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CRNX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.29β · 2% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Aug 31, 2026. For educational research only; not investment advice.